Activist investment firm Ananym Capital Management plans to nominate as many as half a dozen directors to Henry Schein (HSIC), Reuters reported, citing three sources familiar with the matter.
According to the sources, Ananym told the dental and medical distributor that it needs to start searching for a new chief executive officer, cut costs, and optimize capital allocation.
In a November 18 Reuters report, Ananym projected more than $2.5 billion in proceeds from a potential divestment of Henry Schein's medical distribution business that could be used for repurchasing undervalued shares.
Earlier this month, Bank of America Securities adjusted their price target for Henry Schein's shares to $84 from $69 while upgrading the stock to buy.
Henry Schein did not immediately respond to MT Newswires' request for comment late on Wednesday.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。